PreludeDx™ Achieves Significant Growth in DCISionRT® Testing for Breast Cancer Management

PreludeDx™ Reaches New Heights in DCISionRT® Testing

The landscape of breast cancer diagnostics is evolving, particularly for patients diagnosed with ductal carcinoma in situ (DCIS). PreludeDx™, a pioneer in precision diagnostics, recently celebrated a significant milestone for its DCISionRT® test, which provides personalized recurrence risk assessment and evaluates the potential benefits of radiation therapy.

DCIS impacts a considerable number of women in the United States, with approximately 60,000 new cases reported yearly. As the medical community increasingly turns towards personalized treatment strategies, the adoption of DCISionRT® continues to grow within both academic and community cancer centers across the nation.

Impressive Adoption
Since its launch in 2017, DCISionRT® has seen remarkable uptake, with over 3,000 breast cancer specialists ordering the test for more than 45,000 patients. This represents a substantial penetration into the breast cancer care landscape, where now one in three DCIS patients undergoing breast conserving surgery are utilizing the DCISionRT® test to facilitate informed decision-making regarding their treatment options.

The increasing integration of this genomic test into standard care protocols testifies to its importance in enhancing patient outcomes. Clinical studies provide robust support for the utility of DCISionRT®. A key multicenter study, known as the PREDICT trial, involved 2,007 patients across 63 locations and found that DCISionRT® results influenced radiation therapy recommendations in 38% of instances. These findings underscore the test's critical role in guiding physician decision-making in real-world settings.

Clinical Validation and Evidence
Further supporting its efficacy, recent publications illustrate that DCISionRT® delivers significant insights beyond conventional clinical and pathologic factors. An observational study revealed that more than half of patients initially identified as low-risk based on standard criteria were actually reclassified as high-risk when evaluated through the lens of their tumor biology with DCISionRT® results. This reclassification had welcomed implications for treatment, as those patients benefited from radiation therapy.

The significance of DCISionRT® has also gained recognition through its FDA Breakthrough Device designation and CMS Advanced Diagnostic Laboratory Test (ADLT) status. These accolades elevate its credibility as a crucial tool in providing tailored treatment approaches, thus mitigating the risks of overtreatment or undertreatment often faced by DCIS patients.

Dan Forche, President and CEO of PreludeDx™, emphasized the growing acknowledgment of individualized treatment strategies for DCIS in recent years. He predicts that the utilization of DCISionRT® will continue its upward trajectory throughout 2026, further embedding itself in clinical practice as more oncologists adopt the test for new patients.

Transforming Patient Care
DCISionRT® stands out as a clinically validated biologic risk signature, merging molecular biomarkers with clinical data to furnish personalized risk assessments, guiding treatment decisions following breast-conserving surgery. The aim is clear: to enhance shared decision-making between healthcare providers and patients while safeguarding patient well-being throughout their treatment journeys.

As more clinical evidence emerges and acceptance within the care community expands, DCISionRT® is poised to be an integral component of standard discussions in treatment planning for women navigating DCIS. PreludeDx™ remains steadfast in its commitment to advancing precision tools that significantly influence treatment outcomes and streamline healthcare costs for those affected by breast cancer.

For additional insights on how PreludeDx™ is impacting patient care, visit their official website at PreludeDx and engage with their social media channels on X, LinkedIn, Instagram, and Facebook.